Communiqués Glenmark Pharmaceuticals Limited

Actions

GLENMARK

INE935A01035

Produits pharmaceutiques

Marché Fermé - NSE India S.E. Autres places de cotation 13:05:07 17/07/2026			Varia. 5j.	Varia. 1 janv.
2 235,50 ^INR	-2,25%		-2,08%	+9,84%

07/07	Inde : les boutiques de l'aéroport de Mumbai du groupe Adani accusées de vente illégale de sachets de nicotine	RE
06/07	Glenmark Pharmaceuticals lance l'Olanzapine en solution injectable	MT

Communiqués

31/03	Glenmark Pharmaceuticals Canada Inc. Launches Men's GLN-Minoxidil 5% w/w Topical Aerosol Foam in Canadian Retail	AQ
04/03	Glenmark Pharmaceuticals : Specialty SA Receives U.S. FDA Approval for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, with 180-Day Competitive Generic Therapy Exclusivity	PU
27/02	Glenmark Pharmaceuticals : USA to launch Sodium Phosphates Injection USP, 15 mM P/5 mL, 45 mM P/15 mL and 150 mM P/50 mL (3 mM P/mL) Single-Dose Vials	PU
04/02	Glenmark Pharmaceuticals : Q3FY 2025-26	PU
30/01	Glenmark Pharmaceuticals : Q3 FY 2025-26	PU
23/12	Glenmark Pharmaceuticals : USA launches Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial	PU
16/12	Glenmark Pharmaceuticals : Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma	PU
11/12	Glenmark Pharmaceuticals : USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial	PU
27/11	Glenmark Pharmaceuticals : receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility	PU
25/11	Glenmark Pharmaceuticals : Announces Launch of Nebzmart GFB Smartules and Glenmark Airz FB Smartules, World’s First Nebulized Triple Therapy for COPD	PU
25/11	Glenmark Pharmaceuticals : Cosmo and Glenmark Announce Market Authorization of Winlevi (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe	PU
19/11	Cosmo and Glenmark Announce Market Authorization of Winlevi 10 mg/g cream for Treatment of Acne in 15 countries in Europe	AQ
19/11	Glenmark Pharmaceuticals : Q2FY 2025-26	PU
18/11	Glenmark Pharmaceuticals : Cosmo and Glenmark Announce Market Authorization of Winlevi (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe	PU
14/11	Glenmark Pharmaceuticals : Q2 FY 2025-26	PU
14/11	Glenmark Pharmaceuticals : Announces Q2FY26 Results	PU
10/11	Glenmark Pharmaceuticals : Secures China Approval For RYALTRIS, Reinforcing Respiratory Innovation Leadership	PU
04/11	Glenmark Pharmaceuticals : USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial	PU
23/10/25	Glenmark Pharmaceuticals : USA to launch Ropivacaine Hydrochloride Injection USP, 40 mg/20 mL (2mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) Single-Dose Vials	PU
24/09/25	Glenmark Pharmaceuticals : Strengthens Oncology Portfolio with Hengrui’s HER2 Targeting ADC For Multiple Regions	PU
02/09/25	Glenmark Pharmaceuticals : to launch Eribulin Mesylate Injection 1 mg-2 mL (0.5 mg-mL) Single-Dose Vials	PU
29/08/25	Glenmark Pharmaceuticals : FY 2024-25	PU
26/08/25	Glenmark Pharmaceuticals : Q1FY 2025-26	PU
19/08/25	Glenmark Pharmaceuticals : USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial)	PU
14/08/25	Glenmark Pharmaceuticals : Q1 FY 2025-26	PU